vs

Side-by-side financial comparison of Aris Mining Corp (ARMN) and Dermata Therapeutics, Inc. (DRMA). Click either name above to swap in a different company.

Aris Mining Corp is the larger business by last-quarter revenue ($151.1K vs $92.8K, roughly 1.6× Dermata Therapeutics, Inc.). Aris Mining Corp runs the higher net margin — 13.6% vs -1853.3%, a 1866.9% gap on every dollar of revenue.

Endeavour Mining plc is a multinational mining company that owns and operates gold mines in Côte d'Ivoire, Burkina Faso and Senegal. The company is headquartered in London, England, and is listed on the London Stock Exchange. It is a constituent of the FTSE 100 Index.

Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing novel targeted therapies for dermatological diseases including acne, psoriasis and inflammatory skin disorders. It serves U.S. patients and healthcare providers, advancing pipeline candidates through trials to address unmet dermatological care needs.

ARMN vs DRMA — Head-to-Head

Bigger by revenue
ARMN
ARMN
1.6× larger
ARMN
$151.1K
$92.8K
DRMA
Higher net margin
ARMN
ARMN
1866.9% more per $
ARMN
13.6%
-1853.3%
DRMA

Income Statement — Q4 FY2025 vs Q3 FY2023

Metric
ARMN
ARMN
DRMA
DRMA
Revenue
$151.1K
$92.8K
Net Profit
$20.5K
$-1.7M
Gross Margin
44.9%
Operating Margin
30.0%
-1953.3%
Net Margin
13.6%
-1853.3%
Revenue YoY
531.8%
Net Profit YoY
29.1%
EPS (diluted)
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARMN
ARMN
DRMA
DRMA
Q4 25
$151.1K
Q3 23
$92.8K
Q2 23
$31.1K
Q1 23
$37.5K
Q4 22
$42.1K
Q3 22
$-21.5K
Q2 22
$0
Q1 22
$0
Net Profit
ARMN
ARMN
DRMA
DRMA
Q4 25
$20.5K
Q3 23
$-1.7M
Q2 23
$-1.7M
Q1 23
$-2.2M
Q4 22
$-1.7M
Q3 22
$-2.4M
Q2 22
$-2.7M
Q1 22
$-2.8M
Gross Margin
ARMN
ARMN
DRMA
DRMA
Q4 25
44.9%
Q3 23
Q2 23
Q1 23
Q4 22
Q3 22
Q2 22
Q1 22
Operating Margin
ARMN
ARMN
DRMA
DRMA
Q4 25
30.0%
Q3 23
-1953.3%
Q2 23
-5579.4%
Q1 23
-6067.3%
Q4 22
-4067.0%
Q3 22
11384.5%
Q2 22
Q1 22
Net Margin
ARMN
ARMN
DRMA
DRMA
Q4 25
13.6%
Q3 23
-1853.3%
Q2 23
-5479.4%
Q1 23
-5967.3%
Q4 22
-3967.0%
Q3 22
11284.5%
Q2 22
Q1 22
EPS (diluted)
ARMN
ARMN
DRMA
DRMA
Q4 25
$0.02
Q3 23
Q2 23
Q1 23
Q4 22
Q3 22
Q2 22
Q1 22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARMN
ARMN
DRMA
DRMA
Cash + ST InvestmentsLiquidity on hand
$6.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$6.4M
Total Assets
$7.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARMN
ARMN
DRMA
DRMA
Q4 25
Q3 23
$6.6M
Q2 23
$8.4M
Q1 23
$8.8M
Q4 22
$6.2M
Q3 22
$8.1M
Q2 22
$10.6M
Q1 22
$8.2M
Stockholders' Equity
ARMN
ARMN
DRMA
DRMA
Q4 25
Q3 23
$6.4M
Q2 23
$8.0M
Q1 23
$8.1M
Q4 22
$6.0M
Q3 22
$7.5M
Q2 22
$9.7M
Q1 22
$7.9M
Total Assets
ARMN
ARMN
DRMA
DRMA
Q4 25
Q3 23
$7.3M
Q2 23
$8.7M
Q1 23
$9.3M
Q4 22
$6.9M
Q3 22
$9.0M
Q2 22
$11.0M
Q1 22
$9.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARMN
ARMN
DRMA
DRMA
Operating Cash FlowLast quarter
$99.1K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
4.82×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARMN
ARMN
DRMA
DRMA
Q4 25
$99.1K
Q3 23
Q2 23
Q1 23
$-1.6M
Q4 22
$-1.8M
Q3 22
Q2 22
Q1 22
$-2.6M
Cash Conversion
ARMN
ARMN
DRMA
DRMA
Q4 25
4.82×
Q3 23
Q2 23
Q1 23
Q4 22
Q3 22
Q2 22
Q1 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons